Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atesidorsen - Antisense Therapeutics

Next Previous
X
Search
Drug Profile

Atesidorsen - Antisense Therapeutics

Alternative Names: ATL-1103; COR-004

Latest Information Update: 28 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Antisense Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acromegaly
  • No development reported Cancer; Diabetic retinopathy

Most Recent Events

  • 24 May 2018 Antisense Therapeutics plans to conduct an early access programme for atesidorsen in Europe
  • 24 May 2018 Updated efficacy data from a phase II trial in Acromegaly released by Strongbridge Biopharma
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acromegaly in North America (SC, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top